REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot96810.21518/1561-5936-2020-7-8-42-46Original ArticleJAK inhibitors in rheumatoid arthritis: new opportunities and perspectivesShirokovaIrinanoemail@neicon.ruRemedium071220207-8424618032022Copyright © 2020,2020Rheumatoid arthritis (RA) is a pressing medical and social problem, on which researchers around the world are working. One of the solutions that could significantly improve the prognosis of patients’ treatment and their quality of life was discussed within the framework of the VI Rheumatology Summit held online on June 26-27 by the Association of Rheumatologists of Russia with the participation of leading Russian and foreign experts. The method is based on the use of upadacitinib, an innovative drug of JAK inhibitors class.rheumatoid arthritisJAK inhibitorsupadacitinibclinical trialsremissionsafety profilecost-effectivenessревматоидный артритингибиторы янус киназупадацитинибклинические исследованияремиссияпрофиль безопасностиэкономическая эффективность1.Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419. doi: 10.14412/1995-4484-2017-409-419.2.Smolen J.S., van der Heijde D., Machold K.P. et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317.3.Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16.4.Fleischmann R., Pangan A.L., Song I.H. et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019;71(11):1788-1800. doi: 10.1002/art.41032.5.Fleischmann R.M., Genovese M.C., Enejosa J.V. et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454-1462. doi: 10.1136/ annrheumdis-2019-215764.6.Burmester G.R., Kremer J.M., Van den Bosch F. et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT- NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2.7.Genovese M.C., Fleischmann R., Combe B. et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513-2524. doi: 10.1016/ S0140-6736(18)31116-4.8.van Vollenhoven R., Takeuchi T., Pangan A.L. et al. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double- blind, Active-comparator, Multi-center, Multi-country Trial. Arthritis Rheumatol. 2020;10.1002/art.41384. doi: 10.1002/art.41384.9.Smolen J.S., Pangan A.L., Emery P. et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase study. Lancet. 2019;393(10188):2303-2311. doi: 10.1016/S0140-6736(19)30419-2.10.Cohen S., van Vollenhoven R., Winthrop K., Zerbini C. et al. Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase11.Clinical Program. Arthritis Rheumatol. 2019;71(10). Available at: https:// acrabstracts.org/abstract/safety-profile-of-upadacitinib-in-rheumatoid-arthritis- integrated-analysis-from-the-select-phase-3-clinical-program/.12.Rubbert-Roth A., Enejosa J., Pangan A. et al. SAT0151. Efficacy and safety of upadacitinib versus abatacept in patients with active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (select-choice): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:1015-1016. doi: 10.1136/annrheumdis-2020-eular.2059.13.Инструкция по медицинскому применению препарата РАНВЭК (упадацитиниб). Available at: https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=972bc917-f432-4ca8-ad1d-247a7f426b30&t= ссылка доступна на 11.08.2020.14.Smolen J.S., Landewé R.B.M., Bijlsma J.W.J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655.15.Рудакова А.В. Эффективность затрат на ингибиторы янус-киназ при терапии ревматоидного артрита. Современная ревматология. 2020.